Blueprint Medicines Corporation - BPMC STOCK NEWS

Blueprint Medicines Corporation (NASDAQ: BPMC) announced two significant Nature Medicine publications on the EXPLORER and PATHFINDER trials for AYVAKIT® (avapritinib), demonstrating its effectiveness in treating advanced systemic mastocytosis (SM). The studies included approximately 150 patients, showing a 75% overall response rate in both trials. AYVAKIT received FDA approval in June 2021. The data highlights improvements in patient symptoms and survival benefits, supporting Blueprint's commitment to advancing treatment for patients with this rare disorder.

Blueprint Medicines Corporation (NASDAQ: BPMC) has announced a definitive agreement to acquire Lengo Therapeutics for $250 million in cash, with potential additional payments of up to $215 million based on regulatory and sales milestones. This acquisition focuses on Lengo's LNG-451, a promising oral therapy for non-small cell lung cancer (NSCLC) with EGFR exon 20 insertion mutations. The deal is expected to close in Q4 2021, enhancing Blueprint's precision oncology portfolio while addressing significant medical needs for NSCLC patients.

Blueprint Medicines and Zai Lab have entered into an exclusive collaboration to develop BLU-945 and BLU-701 for EGFR-driven non-small cell lung cancer (NSCLC) in Greater China. This partnership aims to leverage Blueprint's innovation in precision therapies and Zai Lab's oncology expertise to address the significant medical needs in the region, where a high percentage of NSCLC patients have EGFR mutations. Blueprint will receive an upfront payment of $25 million and potential milestones totaling $590 million, with Zai Lab managing development costs.

Blueprint Medicines Corporation (NASDAQ: BPMC) announced on November 5, 2021 that it granted non-qualified stock options for 24,373 shares and 12,183 restricted stock units (RSUs) to new employees, effective November 1, 2021. This is part of the 2020 Inducement Plan aimed at incentivizing new hires per NASDAQ Rule 5635(c)(4). The options have an exercise price of $112.82, equal to the stock's closing price on the grant date. Vesting for options and RSUs will occur gradually over several years, contingent on continued employment.

Blueprint Medicines Corporation (NASDAQ:BPMC) reported a net loss of $117.2 million for Q3 2021, contrasting with a net income of $634 million in Q3 2020. Revenue reached $24.2 million, driven by $17.3 million from AYVAKIT, marking a 104% increase from Q2 2021. Collaboration revenues also contributed $6.9 million, while costs surged with R&D expenses at $84.4 million. The company anticipates total revenues for 2021 between $170-$180 million and is advancing clinical trials for its therapeutic candidates.

Blueprint Medicines Corporation (NASDAQ: BPMC) will host a live conference call on October 28, 2021, at 8:30 a.m. ET to discuss its third quarter 2021 financial results and provide a corporate update. Interested participants can dial 844-200-6205 (domestic) or 929-526-1599 (international) using conference ID 963004. A webcast will be accessible on their website and archived for 30 days. Blueprint Medicines focuses on developing precision therapies for cancer and hematologic disorders, with a strong research platform for targeted treatment.

Blueprint Medicines Corporation (NASDAQ: BPMC) announced on October 5, 2021, the grant of non-qualified stock options for 24,068 shares and 12,033 restricted stock units (RSUs) to eight new employees, effective October 1, 2021. These grants are part of their 2020 Inducement Plan, aimed at attracting new talent. The options have an exercise price of $101.72 per share, matching the closing stock price on the grant date. Both the options and RSUs will vest over a period, contingent on continued employment.

Blueprint Medicines Corporation (NASDAQ: BPMC) announced on September 3, 2021, that its Compensation Committee granted stock options for 23,720 shares and 11,858 restricted stock units (RSUs) to 12 new employees. This grant is part of the 2020 Inducement Plan, designed for new hires, effective September 1, 2021. The options have an exercise price of $96.13 per share, equal to the stock's closing price on the grant date. Vesting occurs annually for options and RSUs, contingent on continued employment.

Blueprint Medicines Corporation (NASDAQ: BPMC) announced participation in the Morgan Stanley 19th Annual Global Healthcare Conference, scheduled for September 9, 2021, at 12:30 p.m. ET. Key executives, Kate Haviland and Fouad Namouni, will engage in a fireside chat during the event. A live webcast will be available on their website, with a replay accessible for 30 days post-presentation. Blueprint Medicines is committed to developing precision therapies for cancer and hematologic disorders, continuously advancing its pipeline since its foundation in 2011.